Mangoceuticals, inc. announces completion of first batch of mango ed products for marketing and distribution in mexico and latin american markets

Dallas, texas, may 28, 2024 (globe newswire) -- mangoceuticals, inc. (nasdaq: mgrx) (“mangorx” or the “company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ed), hair growth, weight loss and hormone replacement therapies, is pleased to announce that its subsidiary, mangorx mexico s.a. de c.v. (“mangorx mexico”), in conjunction with its mexico-based pharmacy partner emifarma s.a. de c.v (“emifarma”), has successfully completed its first sample batch of mango ed oral dissolvable tablets (odts) specifically to be marketed and sold in mexico and other eligible latin american (latam) countries.
MGRX Ratings Summary
MGRX Quant Ranking